PSD 509

Drug Profile

PSD 509

Alternative Names: M5004; PSD509

Latest Information Update: 28 May 2014

Price : $50

At a glance

  • Originator Metris Therapeutics
  • Developer Plethora Solutions
  • Class Nonsteroidal anti-inflammatories
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 25 Feb 2013 Discontinued - Phase-I for Pain in United Kingdom (Vaginal)
  • 24 Jan 2011 No development reported - Phase-I for Pain in United Kingdom (Vaginal)
  • 23 Nov 2007 PSD 509 is available for licensing worldwide (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top